Tauvid approved as the first drug to image tau pathology for Alzheimer’s disease

Written by Sharon Salt, Senior Editor

The US FDA has approved a radioactive diagnostic agent, termed Tauvid (flortaucipir F18), as the first drug to image tau pathology in individuals being evaluated for Alzheimer’s disease. Tauvid is indicated for PET imaging of the brain to estimate density and distribution of aggregated tau neurofibrillary tangles. “While there are FDA-approved imaging drugs for amyloid pathology, this is the first drug approved for imaging tau pathology, one of the two neuropathological hallmarks of Alzheimer’s disease, and represents a major advance for patients with cognitive impairment being evaluated for the condition,” stated Charles Ganley (US FDA). The safety and effectiveness of...

To view the full article, please register now for access

It's completely free